Advertisement
Home Tags Sexually Transmitted Diseases: AIDS/HIV

Tag: Sexually Transmitted Diseases: AIDS/HIV

The cancer burden among persons living with HIV is projected to shift by 2030

Cancer Incidences and Burden Expected to Shift in HIV-Positive

Prostate and lung cancer expected to emerge as the most common types by 2030

April 2018 Briefing – HIV & AIDS

Here are what the editors at HealthDay consider to be the most important developments in HIV & AIDS for April 2018. This roundup includes...
For HIV-infected women and their infants

Risk of Adverse Birth Outcomes No Higher With TDF-FTC-LPV/r

Risk not higher compared with ZDV-3TC-LPV/r or TDF-FTC-ATV/r in HIV-infected women in the U.S.
About half of pregnant women with HIV infection underwent cesarean delivery between 1998 and 2013

About Half of Pregnant Women With HIV Have C-Sections

Increase in cesarean delivery among HIV-infected pregnant women from 1998 to 2013

March 2018 Briefing – HIV & AIDS

Here are what the editors at HealthDay consider to be the most important developments in HIV & AIDS for March 2018. This roundup includes...
A non-targeted HIV testing approach in a South African emergency department is acceptable to patients and reveals a high HIV prevalence

Non-Targeted HIV Testing in ER Acceptable to Patients

The program, in South Africa, identifies a high number of cases, including undiagnosed ones
Less than half of women and a quarter of men with recent sexual activity receive sexual risk assessment

CDC: Many Adults Not Receiving Sexual Risk Assessments

47 percent of women, 23 percent of men with recent sexual activity received risk assessment in past year
The burden of two of the most common symptoms in patients living with HIV -- fatigue and muscle aches/joint pains -- is higher in women

For Those With HIV, Symptom Burden Higher in Women

These symptoms, especially fatigue, muscle aches, may be worsened with menopause
From 2008 to 2015

HIV Incidence Down in All Except Men Who Have Sex With Men

Decrease in modeled HIV incidence in all transmission risk groups except minority MSM
Trogarzo (ibalizumab-uiyk) has been approved by the U.S. Food and Drug Administration to treat adult patients living with HIV who have not responded to other antiretroviral medications.

FDA Approves New Medication for Drug-Resistant HIV

Trogarzo is given intravenously once every 14 days in combination with other antiretrovirals